Skip to main content
Home
language-selector-globe Singapore | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Novartis Foundation | en
  • Sandoz | en
  • Global | en
  • Argentina | es
  • Mexico | es
  • United States | en
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Venezuela | es
  • Russia | ru
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Latvia | lv
  • Czech Republic | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Italy | it
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • South Africa | en
  • Turkey | tr
  • Denmark | da
  • Egypt | en
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Korea | ko
  • Singapore | en
  • Taiwan | zh
  • Japan | ja
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en

Language & Country Selector for Mobile

language-selector-globe Singapore

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Russia | ru
  • Lithuania | lt
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Sandoz | en
  • Korea | ko
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Latvia | lv
  • Japan | ja
  • Australia | en
  • Czech Republic | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Denmark | da
  • Italy | it
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Venezuela | es
    • About
      • Novartis in Singapore
      • Strategy
      • Diversity and Inclusion
      • People and Culture
      • Products
      • Contact
      About
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Education and Awareness
      • Patient resources
      • Adverse Event Reporting
      Patients and Caregivers
    • Healthcare Professionals
      • Healthcare professional country resource
      • Products
      • Adverse Event Reporting
      • Novartis Clinical Trials
      Healthcare Professionals
    • ESG
      • Ethical Behavior
        • Code of Ethics
        • SpeakUp
      • Ethics, Risk and Compliance
      • Access
      • Environmental Sustainability
      • Global Health
    • News
      • News Archive
      • Stories
      • Contacts
      News
    • Careers
      • Career Search
      • Meet the teams
      • Learning and Development
      • Personal Growth
      • Early Talent
      • How We Work
      • Well-being
      • Diversity and Inclusion
      • Career Programs
      • Awards and Recognition
      Careers
    • Coronavirus
      Coronavirus
    Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Releases
  • Featured News
  • Stories
  • In the News
icon

October 2021

  • WSD Image_0
    StoryOct 14, 2021 Global Impact
    Restoring vision and hope to thousands in Southeast Asia

September 2021

  • Media ReleaseSep 28, 2021
    Novartis receives approval in Singapore for LEQVIO® (inclisiran), an innovative medication that changes the treatment paradigm for patients with high cholesterol
    Leqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.1, 2 Cardiovascular disease (CVD) is…
  • The Records_Remote Patient Monitoring_Resize_0
    StorySep 24, 2021 Discovery
    Remote Patient Monitoring: The Unstoppable Wave of New Care Models – The Records
  • In The NewsSep 21, 2021
    Singapore approves an innovative medication for patients with high cholesterol
    Leqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.
  • In The NewsSep 13, 2021
    Cell therapy for relapsed cancer patients
    Singapore has successfully treated its first patient using what is known as chimeric antigen receptor T-cell, or CAR-T therapy.

August 2021

  • In The NewsAug 30, 2021
    To fight lymphoma, cancer patient first in Singapore to have T-cells genetically modified outside clinical trials

July 2021

  • In The NewsJul 22, 2021
    Factories: Making the Future
    Ever wondered what it's like inside some of Singapore's factories? This special feature documentary looks at cutting-edge products designed and manufactured in the city-state that will impact the way…
  • In The NewsJul 19, 2021
    Multinational pharmaceutical companies partner with local businesses to help economic recovery

May 2021

  • Galen Growth   Biome partnership_0
    Featured NewsMay 06, 2021
    Galen Growth and Novartis Biome Partner To Launch The Records, a Series of Hybrid Events To Discuss the Future of Healthcare

March 2021

  • Media ReleaseMar 09, 2021
    Novartis receives approval for Kymriah® (tisagenlecleucel) by Health Sciences Authority as Singapore’s first commercially approved CAR-T therapy
    Kymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved in Singapore, is indicated as a one-time treatment manufactured individually for each patient. Novartis works closely…
  • Media ReleaseMar 01, 2021
    Novartis Piqray® - First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval
    Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS…

November 2020

  • Featured NewsNov 03, 2020
    Novartis Singapore LinkedIn Community Guidelines

Pagination

  • 1
  • 2
  • 3
  • 4
  • › Next page

Novartis Singapore

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Product Portfolio
Footer Bottom
© 2022 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Web Accessibility
  • Cookie Settings
  • Site Map
Novartis Site Directory
This site is intended for an audience in Singapore.